
W Ken Redekop

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2173551/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Health-Related Quality of Life and Treatment Satisfaction in Dutch Patients With Type 2 Diabetes. Diabetes Care, 2002, 25, 458-463.	8.6	435
2	Cost-Effectiveness of Prevention and Treatment of the Diabetic Foot: A Markov analysis. Diabetes Care, 2004, 27, 901-907.	8.6	149
3	The Faces of Personalized Medicine: A Framework for Understanding Its Meaning and Scope. Value in Health, 2013, 16, S4-S9.	0.3	138
4	A new test of the construct validity of the CarerQol instrument: measuring the impact of informal care giving. Quality of Life Research, 2011, 20, 875-887.	3.1	75
5	Current Methodological Issues in the Economic Assessment of Personalized Medicine. Value in Health, 2013, 16, S20-S26.	0.3	70
6	The Cost Effectiveness of Apligraf?? Treatment of Diabetic Foot Ulcers. Pharmacoeconomics, 2003, 21, 1171-1183.	3.3	63
7	Diabetes Prevalence in Populations of South Asian Indian and African Origins. Epidemiology, 2011, 22, 563-567.	2.7	57
8	Morbidity and mortality in patients waiting for coronary artery bypass surgery. European Journal of Cardio-thoracic Surgery, 2001, 19, 260-265.	1.4	50
9	A Cross-National Comparative Study of Blood Pressure and Hypertension Between English and Dutch South-Asian- and African-Origin Populations: The Role of National Context. American Journal of Hypertension, 2010, 23, 639-648.	2.0	48
10	Systematic Review of the Accuracy of Dual-Source Cardiac CT for Detection of Arterial Stenosis in Difficult to Image Patient Groups. Radiology, 2013, 267, 387-395.	7.3	48
11	The Economic Evaluation of Medical Devices. Applied Health Economics and Health Policy, 2013, 11, 15-26.	2.1	43
12	DRG systems in Europe: variations in cost accounting systems among 12 countries. European Journal of Public Health, 2014, 24, 1023-1028.	0.3	43
13	Cost-effectiveness of Mechanical Thrombectomy More Than 6 Hours After Symptom Onset Among Patients With Acute Ischemic Stroke. JAMA Network Open, 2020, 3, e2012476.	5.9	30
14	Ethnic differences in antenatal care use in a large multi-ethnic urban population in the Netherlands. Midwifery, 2011, 27, 36-41.	2.3	29
15	Relationships among Self-Management, Patient Perceptions of Care, and Health Economic Outcomes for Decision-Making and Clinical Practice in Type 2 Diabetes. Value in Health, 2010, 13, 138-147.	0.3	28
16	Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. Thrombosis Research, 2015, 136, 69-75.	1.7	28
17	The Cost of Treatment of Alzheimer??s Disease in The Netherlands. Pharmacoeconomics, 2001, 19, 379-390.	3.3	26
18	Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy. Pharmacoeconomics, 2018, 36, 91-103.	3.3	26

W Ken Redekop

#	Article	IF	CITATIONS
19	Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders, 2020, 39, 101929.	2.0	24
20	Comparing Methodologies for the Allocation of Overhead and Capital Costs to Hospital Services. Value in Health, 2009, 12, 530-535.	0.3	23
21	Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e131-e142.	0.4	22
22	Cost-utility analysis of patient care in children with meningeal signs. International Journal of Technology Assessment in Health Care, 2002, 18, 485-96.	0.5	22
23	Health-related quality of life of multiple sclerosis patients: a European multi-country study. Archives of Public Health, 2021, 79, 39.	2.4	21
24	Acute Abdominal Aortic Aneurysms: Cost Analysis of Endovascular Repair and Open Surgery in Hemodynamically Stable Patients with 1-year Follow-up. Radiology, 2006, 240, 681-689.	7.3	18
25	Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30. Value in Health, 2016, 19, 834-843.	0.3	18
26	A Systematic Review of Cost-Effectiveness Studies of Interventions With a Personalized Nutrition Component in Adults. Value in Health, 2021, 24, 325-335.	0.3	17
27	Cost Effectiveness of Continuous Terbinafine Compared with Intermittent Itraconazole in the Treatment of Dermatophyte Toenail Onychomycosis. Pharmacoeconomics, 2001, 19, 401-410.	3.3	16
28	Individualized Angiotensinâ€Converting Enzyme (ACE)â€Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model. Journal of the American Heart Association, 2016, 5, e002688.	3.7	16
29	Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease. Orphanet Journal of Rare Diseases, 2017, 12, 179.	2.7	15
30	Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 557-559.	1.4	13
31	Mobile Safety Alarms Based on GPS Technology in the Care of Older Adults: Systematic Review of Evidence Based on a General Evidence Framework for Digital Health Technologies. Journal of Medical Internet Research, 2021, 23, e27267.	4.3	13
32	Cost-utility of a first-trimester screening strategy versus the standard of care for nulliparous women to prevent pre-term pre-eclampsia in Belgium. Pregnancy Hypertension, 2021, 25, 219-224.	1.4	12
33	The Cost Effectiveness of Tapered versus Abrupt Discontinuation of Oral Cyclosporin Microemulsion for the Treatment of Psoriasis. Pharmacoeconomics, 2001, 19, 599-608.	3.3	11
34	A conceptual disease model for adult Pompe disease. Orphanet Journal of Rare Diseases, 2015, 10, 112.	2.7	10
35	Economic Evaluation in Stratified Medicine: Methodological Issues and Challenges. Frontiers in Pharmacology, 2016, 7, 113.	3.5	10
36	Nocturnal digital surveillance in aged populations and its effects on health, welfare and social care provision: a systematic review. BMC Health Services Research, 2021, 21, 622.	2.2	9

W KEN REDEKOP

#	Article	IF	CITATIONS
37	Decision Making and Priority Setting: The Evolving Path Towards Universal Health Coverage. Applied Health Economics and Health Policy, 2017, 15, 697-706.	2.1	8
38	Modeling the economic impact of medication adherence in type 2 diabetes: a theoretical approach. Patient Preference and Adherence, 2010, 4, 283.	1.8	7
39	Future of Data Analytics in the Era of the General Data Protection Regulation in Europe. Pharmacoeconomics, 2020, 38, 1021-1029.	3.3	7
40	Gray Literature in Evaluating Effectiveness in Digital Health and Health and Welfare Technology: A Source Worth Considering. Journal of Medical Internet Research, 2022, 24, e29307.	4.3	7
41	Cost–effectiveness analyses of diagnostic strategies: a literature survey using the NHS Economic Evaluation Database. Expert Review of Pharmacoeconomics and Outcomes Research, 2006, 6, 41-48.	1.4	6
42	Costs and Effects of Secondary Prevention with Perindopril in Stable Coronary Heart Disease in Poland. Pharmacoeconomics, 2008, 26, 861-877.	3.3	5
43	The cost–effectiveness of blue-light therapy in the treatment of mild-to-moderate psoriasis. Journal of Comparative Effectiveness Research, 2017, 6, 325-335.	1.4	4
44	The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis. Pharmacoeconomics, 2022, 40, 91-108.	3.3	4
45	Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers. BMJ Open, 2015, 5, e007241.	1.9	3
46	Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran. PLoS ONE, 2018, 13, e0205079.	2.5	3
47	What is ahead for health policy and technology in the 2020s?. Health Policy and Technology, 2020, 9, 3-4.	2.5	3
48	Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer. Translational Oncology, 2022, 20, 101418.	3.7	3
49	Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States. Journal of Cancer Policy, 2022, 33, 100346.	1.4	3
50	Trusted writing in social media: FPM International Awards for Medical Writing in Social Media. Health Policy and Technology, 2020, 9, 5-6.	2.5	2
51	Innovative Medical Technology and the Treatment Decision-Making Process in Multiple Sclerosis: A Focus Group Study to Examine Patient Perspectives. Patient Preference and Adherence, 2021, Volume 15, 927-937.	1.8	2
52	How can we discover the most valuable types of big data and artificial intelligence-based solutions? A methodology for the efficient development of the underlying analytics that improve care. BMC Medical Informatics and Decision Making, 2021, 21, 336.	3.0	2
53	Differences in Quality of Antenatal Care Provided by Midwives to Lowâ€Risk Pregnant Dutch Women in Different Ethnic Groups. Journal of Midwifery and Women's Health, 2012, 57, 461-468.	1.3	1
54	Using meta-regression analyses in addition to conventional systematic review methods to examine the variation in cost-effectiveness results – a case study. BMC Health Services Research, 2015, 16, 23.	2.2	1

#	Article	IF	CITATIONS
55	Trusted writing in social media: FPM International Awards for Medical Writing in Social Media. Postgraduate Medical Journal, 2020, 96, 183-183.	1.8	1
56	What are the images used to diagnose and assess suspected strokes?: A systematic literature review of care in four European countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 177-189.	1.4	0
57	Response to â€~Comment on â€~â€~Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategyâ€â€™. Pharmacoeconomics, 2018, 36, 381-382.	3.3	0
58	Tools and Techniques - Statistics: Comments on a cost-effectiveness study of TAVI for patients with inoperable aortic stenosis. EuroIntervention, 2014, 9, 1241-1243.	3.2	0
59	Long-Term Effects of Dexmedetomidine versus Propofol During the Implantation of a Neurostimulator—A Post-Trial Follow-Up Analysis. Journal of Pain Research, 2021, Volume 14, 3631-3636.	2.0	0